Will Budget 2020 be a salve or a sting for India Pharma Inc?
Why API price needs to be part of NPPA’s pricing formula
Will regulators catch up in 2020?
Rationalising pharma trade margins seems next on the list
Lupin sells stakes in Kyowa but its not a Sayonara
After sartans and ranitidine, where will NDMA show up next?
Slaying GMP non-compliance woes
Heeding the clarion call for sustainability
Price caps are a band aid hiding larger issues
CDSCO is blowin’ in the wind
Page 1 of 13
Page 13 of 13